HIFU – High Intensity Focused Ultrasound

 
 

Information

Sonablate® 500

High intensity focused ultrasound

SonaCare Medical has developed the next generation, system for the treatment of localized prostate cancer. Sonablate® 500 HIFU surgical ablation system delivers precise and focused ablative therapy with the possibility of vastly reducing patients side effect profile.  Sonablate 500is powered by the unique T3 Technology, which allows physicians to:

  • target specific tissue using integrated ultrasound imaging and sophisticated planning tools;
  • treat targeted tissue with pinpoint accuracy while sparing untargeted tissue; and
  • track procedure results using real-time ultrasound imaging along with advanced tissue change monitoring software.

The Energy

HIFU, or high intensity focused ultrasound, energy is used to ablate prostate tissue within the body. Ultrasound energy, or sound waves, is focused at a specific location within the prostate called the focal point. At the focal point the tissue temperature rapidly rises to almost 90 degrees Celsius (195 degrees Fahrenheit). The tissue at the focal point is destroyed, while the tissue located outside of the focal lesion remains unharmed. HIFU uses ultrasound energy, not radiation, to destroy targeted tissue so the procedure can be repeated, if necessary.

The Treatment

Sonablate HIFU is a minimally invasive, outpatient treatment choice for prostate cancer that doesn’t use radiation. Sonablate is the only HIFU device for prostate cancer that physicians routinely perform on prostates up to 40cc without previously performing a TURP (transurethral resection of the prostate) procedure.

Sonablate features a fully integrated probe with dual treatment transducers that move robotically to follow the physician’s precise treatment plan. This image guided treatment allows for a customizable treatment plan tailored to each patient’s prostate cancer diagnosis.  This customizable treatment plan  allows the user to treat a wide variety of diagnoses including: benign prostatic hypertrophy (BPH); localized whole-gland prostate cancer treatment (primary/previously untreated); recurrent prostate cancer/radiation failure and recurrence; and Focal therapy/partial gland treatment.

*Source: SonaCare Medical